Incidental induction of secondary bowel disorders in guinea pigs during a batch safety test of veterinary vaccines

Naoyuki Aihara¹,², Mariko Ochiai¹, Noriyuki Horiuchi¹,³*, Atsushi Yamamoto¹, Kasumi Sudo¹, Yoko Ishikawa¹, Koji Oishi¹

¹ National Veterinary Assay Laboratory, Ministry of Agriculture, Forestry and Fisheries, 1-15-1 Tokura, Kokubunji, Tokyo 185-8511, Japan
² Laboratory of Veterinary Pathology, School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan
³ Research Center for Globalagromedicine, Obihiro University of Agriculture and Veterinary Medicine, Obihiro 080-8555, Japan

* Corresponding author. Mailing address: National Veterinary Assay Laboratory, Ministry of Agriculture, Forestry and Fisheries, 1-15-1 Tokura, Kokubunji, Tokyo 185-8511, Japan. Phone: +81-42-321-1841. Fax: +81-42-329-4376. E-mail: horiuchi@obihiro.ac.jp

Running head
SECONDARY BOWEL DISORDERS IN SAFETY TEST
Abstract

Veterinary vaccines are subjected to a safety testing using laboratory animals via intraperitoneal injection per batch. From April 2010 to March 2011, 7 guinea pigs in 4 batch tests exhibited unrecoverable weight loss and/or were found dead. Six guinea pigs had developed intussusception, whereas another one had developed an intestinal obstruction consequent to adhesion. A histopathology revealed that these lesions were associated with inflammatory foci. Other animals than the 7 guinea pig also developed similar inflammatory foci but did not develop bowel disorders. In the retesting of these batches, animals did not exhibited clinical signs, though inflammatory foci were detected. The clinical signs, detected in the primary test, might be due to bowel disorders secondary to an inflammatory response, rather than toxicity.

Keywords: aluminum-based adjuvant, guinea pig, intestinal obstruction, intussusception, laboratory animal batch safety test
During vaccine production, several tests are applied to the final product to meet regulations requiring quality analysis on a batch-to-batch basis [4]. Some tests continue to use animals, although the widely accepted concept of the 3R approach—namely that animal experimentation must be reduced, refined, and replaced—has led to the replacement of most vaccine quality tests with in vitro assays. Existing vaccine authorities have made consistent efforts to follow the 3R approach [1, 5-7]. However, many countries continue to subject final veterinary vaccine products to laboratory animal-based safety testing on a batch-to-batch basis.

In Japan, final products must be subjected to laboratory animal-based batch safety tests, according to the “Minimum Requirements for Veterinary Biological Products,” which is mandated by the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices [10]. Here, one of two tests, the abnormal toxicity test (ATT) or toxicity limit test (TLT; also known as the general safety test, innocuity test, or test for freedom from abnormal toxicity), is applied to the final product as appropriate (see Table 1 for an outline) to identify unexpected toxicities. Briefly, the ATT is applied to veterinary vaccines lacking any hazardous components, whereas the TLT is applied to vaccines containing a component considered virulent in mice and/or guinea pigs or those that are otherwise not suitable for the ATT. Using these tests, final products that cause abnormal weight loss and/or death in an animal model at a certain dose are disqualified. In this study, we describe the disqualification of certain batches after guinea pigs developed intussusception or intestinal obstruction associated with the injected vaccines during batch safety tests. However, further investigation revealed these cases to involve secondary bowel disorders caused by inflammatory responses to the injected vaccines, rather than the toxicity of a contaminant within the tested vaccines.

We tested a total of 186 final product batches of veterinary vaccines. Of these, 118 were subjected to ATT using 244 guinea pigs and 1170 mice, and 68 were subjected
to TLT using 50 guinea pigs and 640 mice. Female Hartley strain specific pathogen-free
guinea pigs (average body weight: 350 g) were purchased from Tokyo Laboratory Animal
Science Co., Ltd (Tokyo, Japan). Female specific pathogen-free ddY mice (age: 5 weeks)
were purchased from Japan SLC, Inc. (Hamamatsu, Japan). All animals were weighed
and checked for clinical symptoms during the test period and were euthanized and
subjected to necropsy and histopathology at the end of the test. Animals that died during
the test period were also subjected to necropsy and histopathology. All procedures applied
to the animals were approved by the Committee on the Ethics of Animal Experiments of
National Veterinary Assay Laboratory (Permit Number: 22-031), and all applicable
international, national, and institutional guidelines for animal care were followed.

Most batches of final products passed batch safety tests. On the other hand, a
few batches failed the tests due to weight loss and/or succumbed to death of experimental
animals (Table 2). All the vaccines, which failed in the tests, contained aluminum-based
adjuvants. Thirty two guinea pigs and 30 mice were subjected to the tests of failed batches
and injected with the same samples in each test. Although most of the subjected animals
did not develop clinical signs, 7 guinea pigs developed clinical signs and/or were found
dead; among them, the 2 guinea pigs with progressive weight loss were subjected to
euthanasia via overanesthesia with isoflurane (Mylan Inc., Canonsburg, PA, U.S.A.).
Necropsy revealed that all animals in the experiments harbored diffuse small white
nodules (diameters: 1–2 mm) on the serous surfaces of abdominal organs. The 6 guinea
pigs with the abnormal symptoms had developed intussusception and another one had
developed an intestinal obstruction associated with intestinal adhesion. The
intussusceptions occurred at the terminal ileum in 4 cases (Fig. 1a) or at the ileocecal
region in 2 cases. The other animals, which had not showed clinical signs in the
experiment, had not developed intussusception or intestinal obstruction despite the white
nodules on serous surface.

Histopathologically, the white nodules on the serous surface were granulomatous
inflammatory foci that consisted of centrally located eosinophilic amorphous deposit, which were surrounded by macrophages, lymphocytes, and fibrin deposits. These granulomatous foci did not invade the muscular layer of intestine. The similar granulomatous inflammatory foci were detected within the sites of intussusception (Fig. 1b) and the focus of intestinal adhesion (Fig. 1c) in the symptomatic 7 guinea pigs. The eosinophilic amorphous deposits, which were found within the granulomatous foci, yielded partly positive response to aluminum staining via the hematoxylin-lake method (Fig. 1d) [11].

The failed batches were subjected to the batch safety test again. No animals developed clinical signs in the tests. Necropsy revealed similar white nodules on the serous surface, which were granulomatous foci with eosinophilic deposit on histopathological evaluation. On the other hand, intussusception or intestinal adhesion was not detected.

To summarize our findings, seven guinea pigs exhibited bowel disorders, and all failed vaccines contained an aluminum-based adjuvant—the most commonly used adjuvant in human—and veterinary vaccines to stimulate an immune response [2]. The adjuvant-induced inflammatory nodules were detected in all the guinea pigs and mice injected with the failed vaccines. However, these nodules did not directly cause clinical symptoms; only inflammatory foci with associated bowel disorder led to clinical symptoms such as intestinal disorders that caused weight loss and/or death in the guinea pigs. Accordingly, we attribute the failures of these batches to the induction of inflammatory foci that led to secondary bowel disorder (e.g., intussusception or intestinal obstruction), rather than unexpected contaminant-related toxicity. The results of the retest, wherein none of the injected animals developed clinical signs despite harboring inflammatory nodules within the abdomen, also support our conclusion. The secondary bowel disorder was observed in the guinea pigs but not in the mice, and might be attributed to the variation in anatomical features between the two species; however the
detailed mechanisms were not detected.

Although the exact mechanism leading to intussusception has not been elucidated, the secondary development of intussusception consequent to a pathological alteration is widely accepted [8]. Briefly, some types of bowel wall or luminal lesions may alter the peristaltic activity and initiate intussusception, after which the intestine begins to undergo invagination. Carcinomas, polyps, Meckel’s diverticulum, colonic diverticulum, strictures, and benign neoplasms have all been identified as triggers for this process [9]. In this study, however, both intussusception and intestinal obstruction likely developed in response to the adjuvant-induced inflammatory nodules.

As noted, other animals injected with the failed vaccines also developed inflammatory nodules without a subsequent secondary bowel disorder. Additionally, no secondary bowel disorders were recorded in animals injected with vaccines that lacked aluminum adjuvant, despite the development of inflammatory foci (unpublished data). Although a previous report investigated the toxicity of aluminum adjuvant [3], no reports have described an associated bowel disorder. Accordingly, we remain unable to explain why only 7 guinea pigs injected with aluminum-containing adjuvant vaccines developed secondary bowel diseases in this study.

To our knowledge, this is the first report to describe intussusception and intestinal obstruction in guinea pigs following intraperitoneal vaccine administration. Although the exact mechanisms of the secondary bowel disorder associated with these injected vaccines have not been elucidated, vaccine inspectors should pay attention to disorders secondary to inflammatory response when encountering unfavorable batch safety test results in laboratory animals.

Acknowledgment

We thank Mayumi Shibayama for her excellent technical assistance.
References


[accessed 28 January 2018].


**Figure legend**

Figure 1. (A) Gross appearance of the intussusception. An intussusception (arrow) occurred at the terminal ileum. (B) Photomicrograph of the intestine at the site of intussusception: centrally located penetrating intestine and laterally located intussuscepted intestine. The intussuscepted intestine was inverted due to intussusception. Inflammatory nodules (arrows) were identified between the serous surfaces of the intestines. HE. Bar, 1 mm. (C) Photomicrograph of the intestinal adhesion: fibrin exudate, infiltration of inflammatory cells, and nodular lesion (arrow) similar to the inflammatory focus detected at the intussusception were noted. HE. Bar, 200 μm. (D) Photomicrograph of the inflammatory nodule stained with aluminum stain (hematoxylin-lake method). Positively stained substance was detected in the nodules. Bar, 200 μm.
<table>
<thead>
<tr>
<th>Test</th>
<th>Animals</th>
<th>Method</th>
<th>Criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal toxicity test</td>
<td>2 guinea pigs and 10 mice</td>
<td>Guinea pig: 2 animals, 5 ml intraperitoneal injection, 7 days of observation  Mice: 10 animals, 0.5 ml intraperitoneal injection, 7–10 days of observation</td>
<td>The product passes the test if no abnormal health signs are observed.</td>
</tr>
<tr>
<td>Toxicity limit test</td>
<td>5 guinea pigs or 10 mice</td>
<td>Guinea pig: 5 animals, 5 ml intraperitoneal injection, 7 days of observation  Mice: 10 animals, 0.5 ml intraperitoneal injection, 7 days of observation</td>
<td>The product passes the test if the animals survive without abnormal signs during the observation and the body weight returns to the initial level within a specified time.</td>
</tr>
<tr>
<td>Tested vaccines</td>
<td>Type of vaccine</td>
<td>Type of test</td>
<td>Adjuvant</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------------</td>
<td>--------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>A</td>
<td>Monovalent bacterial inactivated vaccine</td>
<td>ATT</td>
<td>Aluminum hydroxide gel</td>
</tr>
<tr>
<td>B</td>
<td>Monovalent bacterial inactivated vaccine</td>
<td>ATT</td>
<td>Aluminum hydroxide gel</td>
</tr>
<tr>
<td>C</td>
<td>Multivalent viral inactivated vaccine</td>
<td>ATT</td>
<td>Aluminum phosphate gel</td>
</tr>
<tr>
<td>D</td>
<td>Multivalent viral inactivated vaccine</td>
<td>TLT</td>
<td>Aluminum hydroxide gel</td>
</tr>
<tr>
<td>D</td>
<td>Multivalent viral inactivated vaccine</td>
<td>TLT</td>
<td>Aluminum hydroxide gel</td>
</tr>
<tr>
<td>D</td>
<td>Multivalent viral inactivated vaccine</td>
<td>TLT</td>
<td>Aluminum hydroxide gel</td>
</tr>
<tr>
<td>D</td>
<td>Multivalent viral inactivated vaccine</td>
<td>TLT</td>
<td>Aluminum hydroxide gel</td>
</tr>
</tbody>
</table>

* ATT: abnormal toxicity test, TLT: toxicity limit test, dpi: day post injection